UPDATE: Wells Fargo Reinstates Merck (MRK) at Overweight
Get Alerts MRK Hot Sheet
Price: $131.95 +0.15%
Rating Summary:
24 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
24 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
(Updated - December 9, 2021 5:54 AM EST)
Wells Fargo analyst Mohit Bansal reinstates coverage on Merck (NYSE: MRK) with a Overweight rating and a price target of $90.00.
The analyst comments "Keytruda growth underappreciated as we see $2B upside potential to consensus by 2025. Street is also ignoring MRK's lifecycle management approach for Keytruda LOE. Readouts in 2023-26 should expand multiple. Business development underappreciated."
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $72.28 yesterday.
You May Also Be Interested In
- Merck (MRK) PT Raised to $135 at Wells Fargo
- DA Davidson Starts Progress Software (PRGS) at Buy
- RBC Capital Starts TruBridge Inc (TBRG) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!